Federal Register / Vol. 65, No. 14 / Friday, January 21, 2000 / Notices 3465

IHS area office and States/locality served Scholarship coordinator/address

Navajo Area IHS:

Arizona, New Mexico, Utah ............................................................... Ms. Roselinda Allison, Scholarship Coordinator, Navajo Area IHS, P.O.

Box 9020, Window Rock, AZ 86515, Tele: 520–871–1422.

Oklahoma City Area IHS:

Kansas, Missouri, Oklahoma ............................................................ Ms. Barbara Roy, Scholarship Coordinator, Oklahoma City Area IHS,

Five Corporate Plaza, 3625 NW 56th Street, Oklahoma City, OK

73112, Tele: 405–951–3939.

Phoenix Area IHS:

Arizona, Nevada, Utah ...................................................................... Ms. Lena Fast Horse, Scholarship Coordinator, Phoenix Area IHS, Two

Renaissance Square, 40 North Central Avenue, Suite #600, Phoenix,

AZ 85004, Tele: 602–364–5220.

Portland Area IHS:

Idaho, Oregon, Washington .............................................................. Ms. Darlene Marcellay, Scholarship Coordinator, Portland Area IHS,

1220 SW Third Avenue, Rm. 440, Portland, OR 97204–2892, Tele:

503–326–2015.

Tucson Area IHS:

Arizona, Texas .................................................................................. Mr. Cecil Escalante, Scholarship Coordinator, Tucson Area IHS, 7900

South J. Stock Road, Tucson, AZ 85746, Tele: 520–295–2441.

Other programmatic inquiries may be

addressed to Ms. Rose Jerue, Chief,

Scholarship Branch, Indian Health

Service, Twinbrook Metro Plaza, Suite

100, 12300 Twinbrook Parkway,

Rockville, Maryland, 20852; Telephone

301–443–6197. (This is not a toll free

number.) For grants information, contact

Ms. Margaret Griffiths, Acting Grants

Scholarship Coordinator, Grants

Management Branch, Division of

Acquisition and Grants Operations,

Indian Health Services, Room 100,

12300 Twinbrook Parkway, Rockville,

Maryland, 20852; Telephone 301–443–

0243. (This is not a toll-free number.)

SUPPLEMENTARY INFORMATION: An

addition to the list of priority health

professionals for Indian Health

Scholarships (Professions) that was

published in 62 FR 5443, February 5,

1997, is Coding Specialist-Certificate.

Deletions from the list of priority

health professions for Indian Health

Scholarships (Professions) that was

published in 62 FR 5443, February 5,

1997, are Accounting (B.S.), Business

Administration (B.S., M.B.A.), and

Computer Science (B.S.).

A deletion from the list of priority

career categories for Health Professions

Preparatory scholarships is PreAccounting.

Dated: January 13, 2000.

Michel E. Lincoln,

Deputy Director.

[FR Doc. 00–1403 Filed 1–20–00; 8:45 am]

BILLING CODE 4160–16–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Proposed Data Collection; Comment

Request; Clinical, Laboratory, and

Epidemiologic Characterization of

Individuals at High Risk of Cancer

SUMMARY: In compliance with the

requirement of Section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995,

for opportunity for public comment on

proposed extension of existing data

collection projects, the National Cancer

Institute (NCI), the National Institutes of

Health (NIH) will publish periodic

summaries of proposed projects to be

submitted to the Office of Management

and Budget (OMB) for review and

approval.

Proposed Collection

Title: Clinical, Laboratory, and

Epidemiologic Characterization of

Individuals at High Risk of Cancer.

Type of Information Collection

Request: Extension of OMB No. 0925–

0194 (Expiration date 06/30/00).

Need and Use of Information

Collection: This ongoing research study

will identify cancer-prone persons in

order to learn about cancer risk and

cancer causes in individuals and

families. The primary objectives of this

research study are to utilize clinical,

laboratory, and epidemiologic

approaches in studies of individuals

and families at high risk of cancer to

identify and further characterize cancer

susceptibility factor. Respondents are

members of families in which multiple

cancers are thought to have occurred.

Information about the occurrence of

cancer is collected and reviewed to

determine eligibility for further etiologic

study. Participation is entirely

voluntary. The findings will lead to a

better understanding of the causes and

risk factors for selected cancers, which

may reduce cancer incidence, and

promote the earlier diagnosis of some

cancers.

Frequency of Response: One time.

Affected Public: Individuals or

households.

Type of Respondents: Adults.

The annual reporting burden is as

follows:

Estimated Number of Respondents:

600 per year.

Estimated Number of Responses per

Respondent: 1.

Average Burden Hours Per Response:

75.

Estimated Total Annual Burden

Hours Requested: 450.

The annualized cost to respondents is

estimated at: $4,500. There are no

Capital Costs to report. There are no

Operating or Maintenance Costs to

report.

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) the accuracy of the

agency’s estimates of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) ways to minimize the

burden of the collection of information

on those who are to respond, including

the use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

3466 Federal Register / Vol. 65, No. 14 / Friday, January 21, 2000 / Notices

FOR FURTHER INFORMATION CONTACT: To

request more information on this project

or to obtain a copy of the data collection

plans and instrument, write to Dr.

Margaret Tucker, Chief, Genetic

Epidemiology Branch, National Cancer

Institute, NIH, Executive Plaza South,

Room 7122, 6120 Executive Blvd.,

Bethesda, MD 20892, or call non-tollfree number (301) 496–4375, or E-mail

your request, including your address to:

tuckerp@mail.nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

60 days from the date of this

publication.

Dated: January 12, 2000.

Reesa Nichols,

OMB Project Clearance Liaison.

[FR Doc. 00–1422 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICE

National Institutes of Health

Government-Owned Invention;

Availability for Licensing: ‘‘Therapeutic

Methods to Treat Tumor Cells—

Mutated Anthrax Toxin Protective

Antigen Proteins That Specifically

Target Cells Containing High Amounts

of Cell-Surface Metalloproteinases or

Plasminogen Activators’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

ADDRESSES: Licensing information and

a copy of the U.S. patent application

referenced below may be obtained by

contacing J.R. Dixon, Ph.D., at the Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804 (telephone 301/

496–7056 ext 206; fax 301/402–0220; EMail: jd212g@NIH.GOV). A signed

Confidential Disclosure Agreement is

required to receive a copy of any patent

application.

SUPPLEMENTARY INFORMATION:

Invention Title: ‘‘Mutated Anthrax

Toxin Protective Antigen Proteins that

Specifically Target Cells Containing

High Amounts of Cell-Surface

Metalloproteinases or Plasminogen

Activators.’’

Inventors: Drs. Stephen H. Leppla

(NIDCR), Shi-Hui Liu (NIDCR), Sarah

Netzel-Arnett (NIDCR), Henning

Birkedal-Hansen (NIDCR), and Thomas

H. Bugge (NIDCR).

USPA SN: 60/155,061 [=DHHS Ref.

No. E–293–99/0]—Filed with the

U.S.P.T.O. on Friday, September 24,

1999.

Abstract

Anthrax toxin is a three-part toxin

secreted by Bacillus anthracis consisting

of Protective Antigen (‘‘PA’’, 83kDa),

Lethal Factor (‘‘LF’’, 90 kDa) and Edema

Factor (‘‘EF’’, 89kDa), which are

individually non-toxic. PA, recognized

as central, receptor-binding component,

binds to an unidentified receptor and is

cleaved at the sequence RKKR167 by

cell-surface furin or furin-like proteases

into two fragments: PA63, a 63 kDa Cterminal fragment, which remains

receptor-bound and PA20, a 20 kDa Nterminal fragment, which is released

into the medium. The resulting heterooligomeric complex is internalized by

endocytosis and acidification of the

vesicle causes insertion of the PA63

heptamer into the endosomal membrane

to produce a channel through which LF

or EF translocate to the cytosol, where

LF or EF induce cytotoxic events. Thus,

the combination of PA+LF, named

anthrax lethal toxin, kills animals and

certain cultured cells, due to

intracellular delivery and action of LF,

recently proven to be a zinc-dependent

metalloprotease that is known to cleave

at least two targets, mitogen-activated

protein kinase kinase 1 and 2. The

combination of PA+EF, named edema

toxin, disables phagocyte and probably

other cells, due to the intracellular

adenylate cyclase activity of EF.

Technology

The technology disclosed in the 60/

155,961 patent application relates to

anthrax toxin protective antigen (PA)

mutants in which the furin site is

replaced by sequences specifically

cleaved by matrix metalloproteinases

(MMPs) or plasminogen activators.

These MMP or plasminogen activator

targeted PA mutants are only activated

by plasminogen activator or MMPexpressing tumor cells so as to

specifically deliver a toxin or a

therapeutic agent. This is important

because a wide variety of tumor cell

lines and tissues overexpress MMPs or

plasminogen activators, and this

overexpression is highly correlated to

tumor invasion and metastasis.

Activation of these mutants occurs

mainly on the cell surface and the

targeted agent is then translocated to the

interior of the cell. Current treatment

models include the use of MMP

inhibitors. The disclosed technology

provides a viable alternative to this

model and has the advantage of being

highly targetable and specific to tumor

cells expressing MMPs or plasminogen

activators.

The above mentioned Invention is

available, including any available

foreign intellectual property rights, for

licensing.

Dated: January 12, 2000.

Jack Spiegel,

Division of Technology Development &

Transfer, Office of Technology Transfer.

[FR Doc. 00–1423 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Invention;

Availability for Licensing:

‘‘Compositions and Methods for

Specifically Targeting Tumors—Using

a Blocker Reagent’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

ADDRESSES: Licensing information and a

copy of the U.S. patent application

referenced below may be obtained by

contacting J.R. Dixon, Ph.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804 (telephone 301/

496–7056 ext 206; fax 301/402–0220; EMail: jd212g@NIH.GOV). A signed

Confidential Disclosure Agreement is

required to receive a copy of any patent

application.

SUPPLEMENTARY INFORMATION: Invention

Title: ‘‘Compositions and Methods for

Specifically Targeting Tumors’’

Inventors: Drs. Waldemar Debinski

(EM) and Raj K. Puri (U.S.F.D.A.).

USPA SN: 08/706,207 [=DHHS Ref.

No. E–042–00/0]—Filed with the

U.S.P.T.O. on August 30, 1996.

Abstract

In a chimeric molecule, two or more

molecules that exist separately in their

native state are joined together to form